Search

Your search keyword '"McGuire, Darren"' showing total 54 results

Search Constraints

Start Over You searched for: Author "McGuire, Darren" Remove constraint Author: "McGuire, Darren" Database OpenAIRE Remove constraint Database: OpenAIRE
54 results on '"McGuire, Darren"'

Search Results

1. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial

3. Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes A Secondary Analysis of the DECLARE-TIMI 58 Trial

5. Additional file 1 of Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes

6. Additional file 1 of Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis

7. In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction

9. Meta-analyses of results from randomized outcome trials comparing cardiovascular effects of SGLT2i and GLP-1RA in Asian vs. White patients with and without type 2 diabetes

10. Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial

11. Ertugliflozin and Slope of Chronic eGFR

12. sj-pdf-1-dvr-10.1177_1479164120970933 – Supplemental material for Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12)

13. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

14. 10.1056/NEJMoa2004967

15. Heart Failure Endpoints in Cardiovascular Outcome Trials of SGLT2 inhibitors in Patients with Type 2 Diabetes: A Critical Evaluation of Clinical and Regulatory Issues

16. Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues

17. Range of Risk Factor Levels

18. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA

19. A neglected pool of labour? Frontline service work and hotel recruitment in Glasgow

20. MOESM1 of Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS

21. Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study

22. MOESM1 of Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINAÂŽ): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk

23. MOESM3 of Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINAÂŽ): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk

24. MOESM2 of Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINAÂŽ): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk

25. Quality of Care of the Initial Patient Cohort of the Diabetes Collaborative Registry®

26. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

27. A Multimodality Strategy for Cardiovascular Risk Assessment: Performance in Two Population-Based Cohorts

28. Quality Work and the Moral Economy of European Employment Policy

29. Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis

30. Executive Summary: Heart Disease and Stroke Statistics--2016 Update: A Report From the American Heart Association

31. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association

32. Target Organ Complications and Cardiovascular Events Associated With Masked Hypertension and White-Coat Hypertension: Analysis From the Dallas Heart Study

33. Executive Summary: Heart Disease and Stroke Statistics-2015 Update A Report From the American Heart Association

34. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

35. Heart disease and stroke statistics--2015 update: a report from the American Heart Association

36. Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association

38. Heart disease and stroke statistics--2014 update: a report from the American Heart Association

39. Heart disease and stroke statistics--2013 update: a report from the American Heart Association

40. Electrocardiographic patterns of proximal left anterior descending artery occlusion in ST-elevation myocardial infarction may be modified by three-vessel coronary artery disease

42. The Association of Differing Measures of Overweight and Obesity With Prevalent Atherosclerosis The Dallas Heart Study

44. The Relationship of Body Mass and Fat Distribution With Incident Hypertension Observations From the Dallas Heart Study

45. The Relationship Between C-Reactive Protein and Atherosclerosis Differs on the Basis of Body Mass Index The Dallas Heart Study

46. Associations Among Androgens, Estrogens, and Natriuretic Peptides in Young Women Observations From the Dallas Heart Study

47. Clinical Characteristics, Vascular Function, and Inflammation in Women With Angina in the Absence of Coronary Atherosclerosis The Dallas Heart Study

48. Evaluation of Ranolazine in Patients With Type 2 Diabetes Mellitus and Chronic Stable Angina Results From the TERISA Randomized Clinical Trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina)

50. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality

Catalog

Books, media, physical & digital resources